Revolution Medicines RVMD 深 滬
已收盤 08-22 16:00:00 美东时间
37.01
+0.530
+1.45%
華盛通- 最 高37.91
- 今 開36.63
- 成交量 109.18万股
- 最 低 36.465
- 昨 收 36.48
- 總市值 61.82亿
- 52周最高 62.40
- 市盈率 靜 --
- 換手率 0.65%
- 52周最低 29.17
- 委 比 14.59%
- 總股本 1.67亿
- 歷史最高 62.40
- 量 比 0.64
- 振 幅 3.96%
- 歷史最低 14.08
- 每 手 1
- 風險率 5.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Wells Fargo Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $67
Wells Fargo initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $67.
08-15 18:57
Needham Maintains Buy on Revolution Medicines, Lowers Price Target to $56
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and lowers the price target from $57 to $56.
08-07 18:22
Revolution Medicines Q2 EPS $(1.31) Misses $(1.14) Estimate
Revolution Medicines (NASDAQ:RVMD) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(1.14) by 15.01 percent. This is a 61.73 percent decrease over losses of $(0.81) per share
08-07 04:04
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that it will report financial results for the second quarter of 2025 on August 6, 2025, after market close. A senior management team webcast discussing the results and corporate progress will follow at 4:30 p.m. ET (1:30 p.m. PT) that day. The live and archived webcast can be accessed at https://ir.revmed.com/events-and-presentations. The company develops RAS(ON) inhibitors targeting RAS-addicte...
07-30 20:05
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Revolution Medicines announced the publication of a research paper in *Science* detailing zoldonrasib (RMC-9805), a RAS(ON) G12D-selective covalent inhibitor targeting oncogenic RAS G12D mutations. These mutations are common in cancers like pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Zoldonrasib leverages a novel mechanism involving a protein-protein interface to selectively inhibit RAS G12D, showing promi...
07-24 20:00
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses
Castle Biosciences (NASDAQ:CSTL) said on Wednesday that it has received breakthrough device designation from the U.S. Food and Drug Administration for its DecisionDx-Melanoma test. The DecisionDx-Mel...
07-23 21:18
Revolution Medicines Says FDA Grants Breakthrough Therapy Designation To Elironrasib For Treatment Of Adult Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic NSCLC
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and
07-23 20:02
Revolution Medicines And Iambic Therapeutics Partner To Develop Novel Drug Candidates Using AI Models In Multi-Year Collaboration; Iambic To Receive Up To $25M Through A Combination Of Upfront And Expected Near-Term Performance-Based Milestone Payments For Services Related To Revolution Medicines' Access To Iambic's NeuralPLexer Model For Protein Structure Prediction
Custom-built model will be trained using Revolution Medicines' proprietary data to discover novel drug candidatesIambic to receive up to $25 million through a combination of upfront and expected near-term
07-09 20:16
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
Revolution Medicines and Iambic Therapeutics have entered a multi-year collaboration to develop novel drug candidates using Iambic’s AI models, including NeuralPLexer for protein structure prediction. Under the agreement, Iambic will receive up to $25 million in payments, and both companies will retain rights to exclusive targets. The partnership aims to address challenging oncology targets in RAS-addicted cancers, leveraging Iambic’s advanced AI...
07-09 12:00
